Primary CNS Lymphoma Clinical Trial
— VENOBI-CNSOfficial title:
Chemotherapy Free Treatment With Venetoclax and Obinutuzumab for Relapsed / Refractory Primary CNS Lymphoma Patients (VENOBI-CNS Study) - A Phase IB Study to Assess the Pharmacokinetics in the Cerebrospinal Fluid
Verified date | January 2022 |
Source | Klinikum Stuttgart |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.
Status | Terminated |
Enrollment | 4 |
Est. completion date | November 25, 2021 |
Est. primary completion date | November 25, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion criteria: 1. Age at inclusion = 18 to 80 years, in case of ECOG 0 to 1 age up to 85 years 2. Eastern Cooperative Group performance status (ECOG) = 3 3. Evaluable lymphoma manifestation in the CNS, either contrast-enhanced lesion in the brain parenchyma or measurable meningeal lesions. 4. Biopsy proven CD20 positive PCNSL at initial diagnosis or previous relapse/progression (re-biopsy at study inclusion is not mandatory for inclusion, but strongly recommended if time in remission is longer than 24 months). 5. At least one prior HD-MTX containing chemotherapy application (MTX dosed at = 1 g/m2 body surface area) before progression or relapse. 6. Confirmed relapsed or refractory PCNSL according to the IPCG response criteria with the following definition: Evidence of disease recurrence following PR/CR or uCR or no radiological response (SD or PD) as per the IPCG criteria to prior chemotherapy regimen(s), at least one of them containing high-dose methotrexate. 7. Absolute neutrophil count (ANC) of at least 1'500/µl 8. Platelet count of at least 50'000/µl 9. Adequate liver (alanine aminotransferase [ALAT] and AST = 3.0 x upper limit of normal [ULN] and total bilirubin = 1.5 x ULN) and kidney function (estimated = 30ml/min creatinine clearance according to Cockgroft-Gault formula) 10. Written informed consent 11. Recovery from toxicity from previous anti-lymphoma treatment to = grade 2 Exclusion criteria: 1. Known allergy to venetoclax or other components of the formulation 2. Known allergy to obinutuzumab or other components of the formulation 3. Primary ocular lymphomas without brain parenchymal involvement 4. Lymphoma relapse outside the CNS; extra CNS relapse needs to be ruled out by body CT scans (neck till pelvis) or PET-CT scans. 5. Contraindications for lumbar puncture at the discretion of the clinical investigator 6. Prior exposure to obinutuzumab or venetoclax 7. Other additional anti-lymphoma treatment, e.g. chemotherapy or radiotherapy 8. Active hepatitis B or C 9. HIV seropositivity 10. Chronic use of immunosuppressive drugs, e.g. steroids for systemic autoimmune disease 11. Active infections requiring treatment 12. Other active malignancies (except non-melanoma skin cancer). Prior malignancies without evidence of disease for at least 5 years are allowed 13. Patient is pregnant or breastfeeding, or expecting to conceive or father children within one year of finishing venetoclax and 18 months for obinutuzumab. 14. Prior allogeneic haematopoietic stem cell or solid organ transplantation 15. Therapeutic intervention in setting of other former interventional clinical trial within 30 days before the first IMP administration in VENOBI study; simultaneous participation in registry and diagnostic studies or follow up of an interventional trial is allowed 16. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial 17. Known or persistent abuse of medication, drugs or alcohol 18. Person who is in a relationship of dependence/employment with the sponsor or the investigator 19. Administration of moderate or strong CYP3A inhibitors or inducers within 1 week of initiation of venetoclax dosing. |
Country | Name | City | State |
---|---|---|---|
Germany | Klinikum Stuttgart | Stuttgart | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
Klinikum Stuttgart | University Hospital Freiburg |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetics of venetoclax and obinutuzumab | Serum concentration and CSF concentration (µg/ml) | day 3, 15, and 28 | |
Secondary | Dose limiting toxicities | Defined by CTCAE (version 5.0) | Within the first 6 weeks | |
Secondary | Best lymphoma response achieved during induction | According to IPCG criteria | During induction (3 months) | |
Secondary | Progression-free survival 1 (PFS1) | Time from the date of first dose until date of progression, relapse or death, whichever occurs first | Up to 15 months | |
Secondary | Overall survival | Time from the date of first dose until date of death | Up to 15 months | |
Secondary | Progression-free survival 2 (PFS2) | Time from the start of maintenance venetoclax treatment at week 12 until date of progression, relapse or death, whichever occurs first. | Up to 12 months | |
Secondary | Mutational landscape of lymphoma | NGS test based on FoundationOne Heme® platform | At baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05036564 -
Diagnosis; Objective RespOnse; THErApy
|
N/A | |
Recruiting |
NCT03569995 -
[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04627753 -
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
|
Phase 2 | |
Recruiting |
NCT05518383 -
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
|
Phase 4 | |
Recruiting |
NCT05425654 -
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
|
Phase 2 | |
Active, not recruiting |
NCT04443829 -
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
|
Phase 1 | |
Recruiting |
NCT04006561 -
Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
|
||
Recruiting |
NCT04656431 -
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT04464200 -
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
|
Phase 1 | |
Recruiting |
NCT02934204 -
Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
Recruiting |
NCT04947319 -
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
|
Phase 2 | |
Active, not recruiting |
NCT04134117 -
Tisagenlecleucel In Primary CNS Lymphoma
|
Phase 1 | |
Withdrawn |
NCT03212807 -
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
|
Phase 2 |